Voyageur Pharmaceuticals: From the Earth to the Bottle

January 8, 2020

Radiocontrast products critical to medical imaging

Voyageur Pharmaceuticals Ltd. (previously Voyageur Minerals Ltd.) is focusing on the development of Active Pharmaceutical Ingredients (API) minerals. Using its own mineral resources, Voyageur Pharmaceuticals makes radiocontrast products critical to medical imaging.  

Voyageur is also focused on the development of barite and iodine API minerals for the pharmaceutical market. Further, their goal is to generate positive cash flow from operations through its joint venture with Chief Medical Supply Ltd. - Alberta's only GMP pharmaceutical manufacturer. Moreover, the joint venture contemplates turnkey manufacturing, bottling and distribution of barium radiopharmaceuticals for MRI, X-ray and CT scan applications.

The Company also contemplates extending the joint venture to encompass planned Health Canada registration applications for iodine and bromine products, also for medical applications. Voyageur owns 100% interest in three barium sulfate ("Barite") deposits including two properties suitable in grade for the industrial barite marketplace, and interests in a high-grade iodine, lithium & bromine brine project in Utah, USA.

For more information on Voyageur Pharmaceuticals Ltd. (VM:TSX.V) please fill out the form below.

No tags

Detailed Quote

Invalid Symbol: VM:CA

You might also like

Healthcare
Medicus Pharma: A New Era in Cardio-Sparing Prostate Cancer Treatment

Medicus Pharma is developing a cardio-sparing hormone therapy for prostate cancer patients—targeting both cancer and heart safety.

Healthcare
Medicus Pharma: Targeting Urinary Retention with a Novel Non-Invasive Therapy

Medicus Pharma is introducing a groundbreaking therapy to prevent relapse in men suffering from acute urinary retention due to enlarged prostate.

Content Broadcast on: BNN Bloomberg, CNBC, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!